Skip to main content

Advertisement

Log in

Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In a previous study, we showed that cryotherapy and compression therapy have comparable efficacy in preventing nab-paclitaxel-induced peripheral neuropathy. However, even with cryotherapy or compression therapy, there were patients with National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade ≥ 2 and/or Patient Neurotoxicity Questionnaire (PNQ) grade ≥ D peripheral neuropathies. Therefore, this post hoc analysis was performed to identify predictors of nab-paclitaxel-induced peripheral neuropathy. The clinical data in this post hoc analysis were the data of 38 breast cancer patients receiving chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) at our outpatient chemotherapy center from August 2017 to March 2019. The number of patients was analyzed assuming that there were data for 76 hands. Variables related to the development of nab-PTX-induced peripheral neuropathy were used for regression analysis. Multivariate-ordered logistic regression analysis was performed to identify predictors for the development of nab-PTX-induced peripheral neuropathy. Significant factors included smoking history [odds ratio (OR) 4.64, 95% confidence interval (CI) 1.60–13.5; P = 0.0048] with neuropathy evaluated by CTCAE, body mass index (BMI) (OR 1.13, 95% CI 1.01–1.26; P = 0.039) with neuropathy evaluated by PNQ (sensory), and smoking history (OR 3.80, 95% CI 1.40–10.30; P = 0.0087) and age (OR 1.06, 95% CI 1.01–1.11; P = 0.012) with neuropathy evaluated by PNQ (motor). In conclusion, smoking history, BMI and age were identified as significant predictors of the development of nab-PTX-induced-peripheral neuropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Data not available due to ethical restrictions. Participants of this study did not agree for their data to be shared publicly, so supporting data are not available.

Code availability

N/A.

References

  1. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81:772–81. https://doi.org/10.1002/ana.24951.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–15. https://doi.org/10.1016/j.ejca.2008.04.018.

    Article  CAS  PubMed  Google Scholar 

  3. Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54:587–91. https://doi.org/10.3109/0284186X.2014.995775.

    Article  CAS  PubMed  Google Scholar 

  4. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–9. https://doi.org/10.1007/s00520-014-2255-7.

    Article  PubMed  Google Scholar 

  5. Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013;9:e234–40. https://doi.org/10.1200/JOP.2012.000863.

    Article  PubMed  Google Scholar 

  6. Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. J Natl Cancer Inst. 2018;110:141–8. https://doi.org/10.1093/jnci/djx178.

    Article  CAS  PubMed  Google Scholar 

  7. Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y, Katakami N, Kato H, Hashimoto T, Okuno T, Yamauchi A, Inamoto T. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat. 2016;160:61–7. https://doi.org/10.1007/s10549-016-3977-7.

    Article  CAS  PubMed  Google Scholar 

  8. Tsuyuki S, Yamagami K, Yoshibayashi H, Sugie T, Mizuno Y, Tanaka S, Kato H, Okuno T, Ogura N, Yamashiro H, Takuwa H, Kikawa Y, Hashimoto T, Kato T, Takahara S, Katayama T, Yamauchi A, Inamoto T. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. Breast. 2019;47:22–7. https://doi.org/10.1016/j.breast.2019.06.008.

    Article  PubMed  Google Scholar 

  9. Kanbayashi Y, Sakaguchi K, Ishikawa T, Ouchi Y, Nakatsukasa K, Tabuchi Y, Kanehisa F, Hiramatsu M, Takagi R, Yokota I, Katoh N, Taguchi T. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a prospective self-controlled trial. Breast. 2020;49:219–24. https://doi.org/10.1016/j.breast.2019.12.011.

    Article  PubMed  Google Scholar 

  10. Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Predictors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: a retrospective study in Japan. PLoS ONE. 2021;16: e0261473. https://doi.org/10.1371/journal.pone.0261473.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A. Predictors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018;18:958. https://doi.org/10.1186/s12885-018-4869-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miyamoto T, Hiramoto S, Kanto A, Tsubota M, Fujitani M, Fukuyama H, Hatanaka S, Sekiguchi F, Koizumi Y, Kawabata A. Estrogen decline is a predictor for paclitaxel-induced peripheral neuropathy: clinical evidence supported by a preclinical study. J Pharmacol Sci. 2021;146:49–57. https://doi.org/10.1016/j.jphs.2021.03.001.

    Article  CAS  PubMed  Google Scholar 

  13. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38:3325–48. https://doi.org/10.1200/JCO.20.01399.

    Article  PubMed  Google Scholar 

  14. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scotté F, Taphoorn MJB, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; EONS Education Working Group. Electronic address: eons.secretariat@cancernurse.eu; EANO Guideline Committee. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31:1306–19. https://doi.org/10.1016/j.annonc.2020.07.003.

  15. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. https://doi.org/10.1001/jama.2013.2813.

  16. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17:1483–91. https://doi.org/10.1007/s00520-009-0613-7.

    Article  PubMed  Google Scholar 

  17. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–70. https://doi.org/10.1016/j.pain.2014.09.020.

    Article  PubMed  Google Scholar 

  18. Lauritsen J, Bandak M, Kreiberg M, Skøtt JW, Wagner T, Rosenvilde JJ, Dysager L, Agerbæk M, Daugaard G. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study. J Cancer Surviv. 2021;15:509–17. https://doi.org/10.1007/s11764-020-00944-1.

    Article  PubMed  Google Scholar 

  19. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9: e01312. https://doi.org/10.1002/brb3.1312.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group. Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res. 2017;23:575768. https://doi.org/10.1158/1078-0432.CCR-16-3224.

  21. Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, Kushi LH. BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study. J Natl Cancer Inst. 2016;109: djw206. https://doi.org/10.1093/jnci/djw206.

  22. Timmins HC, Li T, Goldstein D, Trinh T, Mizrahi D, Harrison M, Horvath LG, Friedlander M, Kiernan MC, Park SB. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. J Cancer Surviv. 2021. https://doi.org/10.1007/s11764-021-01012-y.(inpress).

    Article  PubMed  Google Scholar 

  23. Petrovchich I, Kober KM, Wagner L, Paul SM, Abrams G, Chesney MA, Topp K, Smoot B, Schumacher M, Conley YP, Hammer M, Levine JD, Miaskowski C. Deleterious effects of higher body mass index on subjective and objective measures of chemotherapy-induced peripheral neuropathy in cancer survivors. J Pain Symptom Manag. 2019;58:252–63. https://doi.org/10.1016/j.jpainsymman.2019.04.029.

    Article  Google Scholar 

  24. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159:327–33. https://doi.org/10.1007/s10549-016-3939-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, Battaglini E, Wyld D, Henderson RD, Grimison P, Ke H, Geelan-Small P, Marker J, Wall B, Goldstein D. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open. 2021;4: e2036695. https://doi.org/10.1001/jamanetworkopen.2020.36695.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all the patients and medical staff at University Hospital, Kyoto Prefectural University of Medicine who were involved in this study.

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

YK concept and design, data acquisition, data analysis, data interpretation, manuscript writing; KS and TI concept and design, data acquisition, data interpretation; YT data acquisition, data interpretation; RT and IY concept and design, data analysis; NK and KT concept and design; TT concept and design, data acquisition, data interpretation, supervision of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yuko Kanbayashi.

Ethics declarations

Conflict of interest

Isao Yokota has received a speaker’s fee from Chugai Pharmaceutical Co., Ltd. Norito Katoh has been a speaker and investigator for Taiho Pharmaceutical Co., Ltd. Tetsuya Taguchi received a speaker’s fee and research funds from Taiho Pharmaceutical and Chugai Pharmaceutical Co., Ltd. All other authors declare that they have no conflicts of interest concerning this work.

Consent for publication

Written, consent for publication was obtained from all patients prior to their enrollment.

Ethical approval

This trial was approved by the Medical Ethics Review Committee of Kyoto Prefectural University of Medicine, in accordance with the tenets of the Declaration of Helsinki (approval no. ERB-C-906-1).

Informed consent

Written, informed consent was obtained from all patients prior to their enrollment.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanbayashi, Y., Sakaguchi, K., Ishikawa, T. et al. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial. Med Oncol 39, 153 (2022). https://doi.org/10.1007/s12032-022-01754-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-022-01754-4

Keywords

Navigation